FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Approves Takedas Orzeyful for Narcolepsy Type 1

[ Price : $8.95]

FDA approves Takedas Orzeyful as the first drug to treat all symptoms of narcolepsy type 1 in adults.

Fresenius Recalls Morphine Injection Syringe Lot Due to Labeling Mix-Up

[ Price : $8.95]

Fresenius Kabi recalls one lot of Simplist (morphine sulfate injection USP) 2 mg/1 mL prefilled syringes after discovering a label...

Multiple Violations in Brunner Hygiene Unapproved New Drugs

[ Price : $8.95]

FDA warns Germanys Thomas Brunner Hygiene about CGMP and other violations in its production of unapproved and misbranded antipersp...

Jazz to Remove Zepzelca Second-Line Indication

[ Price : $8.95]

Jazz Pharma says it will seek FDA approval to remove Zepzelcas (lurbinectedin) second-line metastatic small cell lung cancer indi...

Allergan sBLA for Botox Accepted for Review

[ Price : $8.95]

FDA accepts for review an Allergan Aesthetics supplemental BLA for Botox Cosmetic (onabotulinumtoxinA) for the temporary improveme...

FDA Warns of High-Risk Issue With BD Intraosseous Needle Sets

[ Price : $8.95]

FDA issues an early alert warning healthcare providers not to use certain Becton Dickinson intraosseous vascular access needle set...

Liebel-Flarsheim Recalls Optiray Imaging Contrast Agent

[ Price : $8.95]

Liebel-Flarsheim recalls one lot of its Optiray Imaging Bulk Package 350 radiographic contrast agent after identifying particulate...

Electronic Common Document Updated Support Package Out

[ Price : $8.95]

The International Council for Harmonization says its electronic common technical document working group has issued updated support...

Arrowhead Acquires Priority Voucher to Speed Plozasiran Expanded Indication

[ Price : $8.95]

Arrowhead Pharmaceuticals agrees to acquire an FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party ...

Suggestions for FDA Draft Guidance on Some Oncology Studies

[ Price : $8.95]

Four stakeholders praise an FDA draft guidance on streamlining some oncology nonclinical safety studies and recommend improvements...